Therapeutic drug monitoring of antiretrovirals for people with HIV

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Kredo, Tamara ^a   Van Der Walt, Jan Stefan ^a   Siegfried, Nandi ^b   Cohen, Karen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MORBIDITY; MORTALITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 70049116829     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007268.pub2     Document Type: Review

References (66)

1. Best BM, Goicoechea M, Witt M, Miller L, Daar E, Diamond C, et al.A randomised controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 2007;46(4):433-442. (Pubitemid 350098694)
2. ossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, et al.GENOPHAR: a randomised study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Medicine 2004;5:352-359.
3. Burger D, Hugen P, Reiss P, Gyssens Inge, Schneider M, Kroon F, et al.Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003;17:1157-1165. (Pubitemid 36667758)
4. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomised prospective study to evaulate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002;16:2311-2315. (Pubitemid 35449017)
5. Crommentuyn K, Huitema A, Brinkman K, van der Ende M, de Wolf F, Beijnen J. Therapeutic drugmonitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in ATHENA study. Journal of Acquired Immune Deficiency Syndrome 2005;39(2):249-250. (Pubitemid 40741125)
6. Fletcher C, Anderson P, Kakuda T, Schacker, Henry K, Gross C, Brundage R. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551-560. (Pubitemid 34218850)
7. Khoo S, Lloyd J, Dalton M, Bonington A, Hart E, Gibbons S, et al.Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN) - a randomised controlled trial of therapeutic drug monitoring and adherence suppor. Journal of Acquired Immune deficiency Syndrome 2006;41:461-467. (Pubitemid 43756162)
8. Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A. A randomised controlled trial to evaluate antiretroviral salvage therapy guided by rule-based or phenotyoe-driven HIV-1 genotypic drug-resistance interpretation with or without concentration controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) Study. Clinical Infectious Diseases 2005;40:1828-1836. (Pubitemid 40799955)
9. Clevenbergh P, Durant J, Garraffo R, Kirstetter M, Daures JP, Dellamonica P and Infectio-SUD Group. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentre randomised controlled trial: 12 week results. 8th Conference on Retroviruses and Opportunistic Infections. 2001.
10. Clevenbergh P, Bozannat MC, Kirstetter M, Durant J, Cua E, del Giudice P, et al.Variable virological outcomes according to the centre providing antiretroviral therapy within the PharmAdapt Clinical Trial. HIV Clin Trials 2003;4(2):84-91. (Pubitemid 36410911)
11. Durant J, Clevenbergh P, Garraffo R, halfon P, Icard S, del Giudice P, et al.Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotype-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000;14:1333-1339. (Pubitemid 30459505)
12. Fletcher C, Testa M, Brundage R, Chesney M, Haubrich R, Acosta E, et al.Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group 359. Journal of Acquired Immune Deficiency Syndrome 2005;40(3):301-306 (Pubitemid 41533070)
13. Hugen P, Langebeek N, Burger D, Zomer B, van Leusen R, Schuurman R, et al.Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndrome 2002;30:324-334 (Pubitemid 34774081)
14. * Kakuda TN, Page LM, Schacker T, Acosta EP, Anderson PL, Brundage RC, et al.Concentration-controlled (CC) antiretroviral therapy with zidovudine (ZDV), Lamivudine (3TC), Indinavir (IDV): pharmacokinetics. 6th Conference on Retroviruses and Opportunistic Infections. 1999.
15. Kakuda T, Page L, Anderson P, Henry K, Schacker T, Rhame F, et al.Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial agents and chemotherapy 2001;45(1):236-242 (Pubitemid 32039121)
16. Van Leth F, Kappelhoff BS, Johnson D, Losso MH, Boron-Kaczmarska A, Saag MS, et al.Pharmacokinetic parameters of nevirapne and efavirenz in relation to antiretroviral efficacy. AIDS Research and Human Retroviruses 2006;22(3):232-239
17. Demeter L, Jiang H, Mukherjee H, Morse G, DiFrancesco R, Klingman K, et al and the A5146 Study Team. A Prospective, Randomized, Controlled, Open-label Trial Evaluating the Effect of Therapeutic Drug Monitoring and Protease Inhibitor Dose Escalation on Viral Load Responses in Antiretroviral-experienced, HIV-infected Patients with a Normalized Inhibitory Quotient. Conference of Retroviruses and Opportunistic Infections. 2008.
18. Alexander C, Asselin J, ting L, Montaner J, Hogg R, Yip B, et al.Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. Journal of Infectious Diseases 2003;188:541-548.
19. Back D, Khoo S, Gibbons S, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. British Journal of Clinical pharmacology 2001;51:301-308. (Pubitemid 32391484)
20. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al.Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16 Suppl 1:S5-37. (Pubitemid 34409031)
21. Back D, Blaschke T, Boucher CA, Burger D, Fletcher C, Flexner C, et al.Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. www.HIVPHARMACOLOGY.com accessed August 2008; Vol. version 1 2003.
22. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Therapeutic Drug Monitoring 2006;28(3):468-473. (Pubitemid 44314939)
23. Back D, Blaschke T, Boucher CA, Burger D, Fletcher C, Flexner C, et al.Optimising TDM in HIV Clinical Care, a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents, version 1.0 (April 2003). www.hivpharmacology.com (accessed 22 August 2008).
24. Bartlett J, DeMasi R, Quinn J, Moxham C, Rousea F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377. (Pubitemid 32663904)
25. Best BM, Goicoechea M, Witt Mallory, Miller L, Daar E, Diamond C, et al.A randomised controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 2007;46(4):433-442. (Pubitemid 350098694)
26. Gazzard B, Bernard E, Boffito M, Churchill D, Edwards S, Fisher M, et al.British HIV Association (BHIVA) guidelines for treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine 2006;7:487-503. (Pubitemid 44742349)
27. Boffito M, Acosta E, Burger D, Fletcher C, Flexner C, Garaffo R, et al.Current status and future prospects of therapeutic drugmonitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy 2005;10:375-392. (Pubitemid 41151016)
28. Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, et al.GENOPHAR: a randomised study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Medicine 2004;5:352-359. (Pubitemid 39276333)
29. Burger D, Hugen P, Reiss P, Gyssens Inge, Schneider M, Kroon F, et al.Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003;17:1157-1165. (Pubitemid 36667758)
30. Carosi G, Torti C, Andreoni M, Antinori A, Bonora S, Borderi M, et al.Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). http://jac.oxfordjournals.org/cgi/reprint/dkl113v1.pdf (accessed 15 October 2007).
31. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomised prospective study to evaulate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002;16:2311-2315. (Pubitemid 35449017)
32. Crommentuyn K, Huitema A, Brinkman K, van der Ende M, de Wolf F, Beijnen J. Therapeutic drugmonitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in ATHENA study. Journal of Acquired Immune Deficiency Syndrome 2005;39(2):249-250. (Pubitemid 40741125)
33. De Maat MMR, Ter Heine R, Mulder JW, Meenhorst PL, Mairuhu ATA, VanGorp ECM, et al.Incidence and risk factors for nevirapine-associated rash. European Journal of Clinical Pharmacology 2003;59:457-462. (Pubitemid 37214954)
34. De Requena DG, Bonora S, Garazzino S, Sciandra M, DêAvolio A, Raiteri R, et al.Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrobial Agents and Chemotherapy 2005;49:3966-3969. (Pubitemid 41233062)
35. Deeks S. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-2011.
36. Delfraissy J.F. on behalf of consensus panel of French reserachers, clinicians, community advocates. New French guidelines for antiretroviral treatment. HIV Medicine 2000;1:133-136.
37. Demeter LM, Mukherjee L, DiFrancesco R, Jiang H, Dicenzo R, Bastow B, et al.The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients. HIV Clinical Trials 2008;9:61-72. (Pubitemid 351214242)
38. Panel on Antiretroviral Guidelines for Adult, Adolescents. Guidelines for the use of antitiretrovirals in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/ adultandadolescentGL.pdf (accessed 7 July 2007).
39. Fletcher CV, Kawle SP, Kakuda T, Anderson PL, Weller D, Bushmn LR, et al.Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000;14:2137-2144. (Pubitemid 30792487)
40. Fletcher C, Anderson P, Kakuda T, Schacker, Henry K, Gross C, Brundage R. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551-560. (Pubitemid 34218850)
41. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology 2000;40:651-676. (Pubitemid 30340696)
42. Gibbon C. South African Medical Formulary. 7th Edition. Cape Town: Health and Medical Publishing Group, SAMA, 2005.
43. Hammer SM, Squires KE, Hughes MD, Grimes J, Demeter L, Currier J, et al.A controlled trial of two nucleoside analogues plus indinavir in persons with Human Immunodeficiency Virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997;337(11):725-733. (Pubitemid 27417971)
44. Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clinical Infectious Diseases 2005;40:22-23.
45. Hammer S, Eron J, Reiss P, Schooley R, Thompson M, Walmsley S, et al.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. Journal of America Medical Association 2008;300(5):555-570.
46. Hammer S, Saag M, Schechter J, Montaner M, Schooley R, Jacobson D, et al.Treatment for adult HIV infection - recommendations of the International AIDS Society -USA Panel. JAMA 2006;296(7):827-843. (Pubitemid 44223106)
47. Kappelhoff B, Crommentuyn K, de Maat M, Mulder J, Huitema A, Beijnen J. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clinical Pharmacokinetics 2004;43(13):845-853. (Pubitemid 39447031)
48. Kappelhoff BS, Van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montanella F, et al.Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antiviral Therapy 2005;10:489-498. (Pubitemid 41059195)
49. Khoo S, Lloyd J, Dalton M, Bonington A, Hart E, Gibbons S, et al.Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN) - a randomised controlled trial of therapeutic drug monitoring and adherence support. Journal of Acquired Immune deficiency Syndrome 2006;41:461-467. (Pubitemid 43756162)
50. La Porte CJL, Back D, Blaschke T, Boucher CAB, Fletcher C, Flexner C, et al.Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006;3:4-14.
51. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al.Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet 1999;353:863-868. (Pubitemid 29126872)
52. Lohse N, Hansen A, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. Journal of Antimicrobial Chemotherapy Advance Access (accessed 8 July 2007). (Pubitemid 47303950)
53. Mocroft A, Phillips AN, Gatell J, Ledegerber B, Fisher M, Clurneck N, et al.Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007;370:407-413. (Pubitemid 47176633)
54. Molto J, Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. Journal of HIV Therapy 2004;9(4):75-78.
55. Murphy R, Brun S, Hick C, Eron J, Gulick R, King M etal. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15:1-9. (Pubitemid 32055772)
56. Pallela F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 1998;338(13):853-860. (Pubitemid 28135961)
57. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton S, van Lunzen J, et al.Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Archives of Internal Medicine 2000;160:1123-1132. (Pubitemid 30227022)
58. Raboud JM, Montaner JSG, Conway B, Rae S, Reiss P, Sella S, et al.Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12:1619-1624. (Pubitemid 28418331)
59. Rayner C, Dooley M, Nation R. Antivirals for HIV. In: Burton M, Schentag J, Shaw L, Evans W editor(s). Applied pharmacokinetics & pharmacodynamics, Principles of therapeutic drug monitoring. 4th Edition. Baltimore: Lippincott Williams & Wilkins, 2006:355-409.
60. National Department of Health South Africa. National Antiretroviral Treatment Guidelines. Jacana, 2004.
61. Tassie JM, Szumulin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource poor settings: the experience of Medicins Sans Frontieres. AIDS 2003;17:1995-1997. (Pubitemid 37074829)
62. Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A. A randomised controlled trial to evaluate antiretroviral salvage therapy guided by rule-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) Study. Clinical Infectious Diseases 2005;40:1828-1836. (Pubitemid 40799955)
63. Veldkamp AI, Weverling GJ, Lange JMA, Montaner JSG, Reiss P, Cooper DA, et al.High exposure to nevirapine in plasma is associated with improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-1095. (Pubitemid 32549859)
64. Charles Gilks, Marco Vitorio and the World Health Organisation guidelines development group. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2006 revision. http://www.who.int/hiv/pub/guidelines/adult/en/index.html (accessed July 2007).
65. UNAIDS/ WHO Epidemiological Fact Sheets on HIV and AIDS, 2008 Update. http://www.who.int/GlobalAtlas/predefinedReports/EFS2008/index.asp? strSelectedCountry=(accessed 18 August 2008).
66. French expert group's recommendations for medical managment of HIV infection 2006. http://www.sante.gouv.fr/pdf/dossiers/sidahop/delfraissy.pdf (accessed 7 July 2007).